Perrigo Company plc (PRGO) Current Ratio
- Current ratio · latest quarter: Value 2.32×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-27; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 2.32× | Current assets / current liabilities. $2.45B ÷ $1.05B ≈ 2.32× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 2.45B USD | Assets, Current |
| Current obligations | 1.05B USD | Liabilities, Current |
| Cash and equivalents | (m) | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Available-for-sale Securities, Current |
| Customer receivables | 709.90M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 1.06B USD | Inventory, Net |
| Payables | 400.40M USD | Accounts Payable, Current |
| Borrowing debt due within one year | 11.40M USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-27 | $2.45B | $1.05B | (m) | (m) | $709.90M | $1.06B | $400.40M | $11.40M | 2.32× |
| 2026-03-28 | $2.71B | $997.60M | (m) | (m) | $697.10M | $1.12B | $434.80M | $11.40M | 2.72× |
| 2025-12-31 | $2.80B | $1.01B | (m) | (m) | $612.80M | $1.15B | $474.50M | $36.60M | 2.76× |
| 2025-09-27 | $2.88B | $1.15B | $432.10M | (m) | $644.40M | $1.23B | $469.70M | $36.60M | 2.51× |
| 2025-06-28 | $2.62B | $1.13B | $454.20M | (m) | $678.20M | $1.22B | $489.00M | $36.40M | 2.32× |
| 2025-03-29 | $2.53B | $1.07B | $409.90M | (m) | $716.80M | $1.16B | $502.30M | $36.20M | 2.36× |
| 2024-12-31 | $2.48B | $1.04B | (m) | (m) | $642.30M | $1.08B | $495.20M | $36.40M | 2.38× |
| 2024-09-28 | $3.71B | $1.45B | $1.46B | (m) | $785.90M | $1.13B | $458.50M | $440.70M | 2.56× |
| 2024-06-29 | $2.96B | $1.49B | $542.80M | (m) | $726.00M | $1.12B | $471.50M | $440.80M | 1.99× |
| 2024-03-30 | $2.81B | $1.55B | $658.50M | (m) | $780.00M | $1.12B | $453.70M | $440.60M | 1.81× |
| 2023-12-31 | $2.83B | $1.59B | (m) | (m) | $739.60M | $1.14B | $477.70M | $440.60M | 1.79× |
| 2023-09-30 | $2.77B | $1.01B | $598.30M | (m) | $737.80M | $1.15B | $433.10M | $38.10M | 2.74× |
| 2023-07-01 | $2.77B | $1.06B | $555.20M | (m) | $754.10M | $1.17B | $470.50M | $38.40M | 2.62× |
| 2023-04-01 | $2.74B | $1.09B | $553.00M | (m) | $738.70M | $1.18B | $505.20M | $38.80M | 2.52× |
| 2022-12-31 | $2.72B | $1.11B | (m) | (m) | $697.10M | $1.15B | $537.30M | $36.20M | 2.44× |
| 2022-10-01 | $2.58B | $1.01B | $468.70M | (m) | $707.70M | $1.09B | $461.40M | $33.50M | 2.55× |
| 2022-07-02 | $2.65B | $1.01B | $485.30M | (m) | $750.30M | $1.08B | $490.40M | $30.80M | 2.61× |
| 2022-04-02 | $3.94B | $981.30M | $1.97B | (m) | $679.30M | $1.02B | $479.60M | $4.60M | 4.01× |
| 2021-12-31 | $3.86B | $1.59B | $1.86B | (m) | $652.90M | $1.02B | $411.20M | $603.80M | 2.43× |
| 2021-10-02 | $4.23B | $2.00B | $2.08B | (m) | $686.20M | $1.09B | $405.60M | $629.40M | 2.11× |
| 2021-07-03 | $4.42B | $1.98B | $317.50M | (m) | $620.20M | $1.12B | $402.40M | $630.10M | 2.23× |
| 2021-04-03 | $4.49B | $1.45B | $470.90M | (m) | $641.00M | $1.14B | $430.30M | $35.80M | 3.10× |
| 2020-12-31 | $3.13B | $1.38B | $631.50M | (m) | $593.50M | $1.06B | $451.60M | $37.30M | 2.27× |
| 2020-09-26 | $3.40B | $1.34B | $849.40M | (m) | $1.10B | $1.10B | $536.40M | $16.50M | 2.54× |
| 2020-06-27 | $3.80B | $1.86B | $1.46B | (m) | $1.00B | $1.03B | $489.10M | $606.50M | 2.05× |
| 2020-03-28 | $3.05B | $1.64B | $510.40M | (m) | $1.30B | $930.80M | $555.80M | $287.80M | 1.86× |
| 2019-12-31 | $2.73B | $1.34B | $354.30M | (m) | $1.24B | $967.30M | $520.20M | $3.40M | 2.04× |
| 2019-09-28 | $2.74B | $1.32B | $398.50M | (m) | $1.10B | $990.50M | $524.90M | $3.10M | 2.07× |
| 2019-06-29 | $3.44B | $1.79B | $1.06B | (m) | $1.12B | $940.50M | $513.70M | $398.80M | 1.92× |
| 2019-03-30 | $3.01B | $1.83B | $837.90M | (m) | $1.12B | $912.90M | $549.20M | $467.90M | 1.64× |
| 2018-12-31 | $2.90B | $1.54B | $551.10M | (m) | $1.07B | $878.00M | $474.90M | $190.20M | 1.89× |
| 2018-09-29 | $2.77B | $1.49B | $444.20M | (m) | $1.08B | $885.30M | $503.60M | $194.20M | 1.85× |
| 2018-06-30 | $2.78B | $1.54B | $526.50M | (m) | $1.13B | $883.80M | $533.40M | $197.70M | 1.81× |
| 2018-03-31 | $2.90B | $1.39B | $687.30M | (m) | $1.12B | $843.80M | $512.20M | $58.00M | 2.08× |
| 2017-12-31 | $2.82B | $1.44B | $678.70M | (m) | $1.13B | $806.90M | $450.20M | $70.40M | 1.96× |
| 2017-09-30 | $2.97B | $1.73B | $775.90M | (m) | $1.08B | $821.90M | $477.10M | $417.10M | 1.72× |
| 2017-07-01 | $2.82B | $1.63B | $760.80M | (m) | $1.07B | $818.10M | $480.80M | $406.90M | 1.73× |
| 2017-04-01 | $5.11B | $2.49B | $3.08B | (m) | $1.05B | $800.20M | $476.30M | $1.18B | 2.06× |
| 2016-12-31 | $2.81B | $1.84B | $622.30M | (m) | $1.18B | $795.00M | $471.70M | $572.80M | 1.53× |
| 2016-10-01 | $2.62B | $1.51B | $362.70M | (m) | $1.12B | $884.60M | $502.90M | $265.00M | 1.73× |
| 2016-07-02 | $3.03B | $2.06B | $641.80M | (m) | $1.19B | $894.60M | $509.10M | $758.10M | 1.47× |
| 2016-04-02 | $3.01B | $2.22B | $588.90M | (m) | $1.19B | $905.10M | $557.20M | $650.70M | 1.36× |
| 2015-12-31 | $2.79B | $2.55B | $417.80M | (m) | $1.19B | $898.70M | $555.80M | $1.06B | 1.09× |
| 2015-09-26 | $2.88B | $1.66B | $506.50M | $16.50M | $1.23B | $888.00M | $541.20M | $58.20M | 1.73× |
| 2015-06-27 | $3.23B | $1.75B | $785.60M | (m) | $1.21B | $935.70M | $709.30M | $153.30M | 1.85× |
| 2015-03-28 | $5.13B | $1.28B | $3.43B | $21.80M | $881.70M | $637.00M | $323.20M | $355.60M | 3.99× |
| 2014-12-27 | $5.36B | $1.32B | $3.60B | $20.00M | $924.70M | $641.80M | $302.70M | $362.30M | 4.05× |
| 2014-09-27 | $2.63B | $1.02B | $891.50M | $21.60M | $869.40M | $656.80M | $309.00M | $141.50M | 2.59× |
| 2014-06-28 | $2.55B | $1.07B | $799.50M | (m) | $931.50M | $629.90M | $364.30M | $143.70M | 2.38× |
| 2014-03-29 | $2.30B | $953.00M | $609.40M | $7.70M | $793.10M | $693.50M | $325.30M | $141.70M | 2.42× |
| 2013-12-28 | $2.29B | $961.80M | $521.10M | $85.50M | $769.80M | $702.30M | $306.70M | $141.20M | 2.38× |
| 2013-09-28 | $4.73M | $13.32M | $135.00 | (m) | (m) | (m) | (m) | (m) | 0.35× |
| 2013-06-29 | $2.24B | $749.40M | $779.90M | $0.00 | $651.90M | $703.90M | $382.00M | $41.20M | 2.98× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |